…
ProText Mobility, Inc., a biotech company, engages in the development of pharmaceutical botanical medicines. Its medicines are formulated with highly-bioavailable plant extracts. The company is based in Boca Raton, Florida. ProText Mobility, Inc. is a subsidiary of Plandaí Biotechnology, Inc.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Publicly available information on Protext Mobility Inc (PINK: TXTM) is limited and corporate disclosures are sparse, preventing a clear, independently verifiable description of its core operations. Any long-term growth would depend on the company filing current financial statements, defining and scaling a viable business model, and executing on identifiable product or customer milestones, factors that may benefit investors if achieved.
The most important investment risks are lack of transparent and current financial reporting, low liquidity and disclosure standards associated with OTC Pink listings, potential for significant dilution or corporate inactivity, and general uncertainty around business continuity.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2013-12-31 | 2012-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2013-12-31 | 2012-12-31 |
| Income before tax | -0.55M | -0.29M | -0.25M | -1.45M | -2.17M |
| Net income | -0.55M | -0.29M | -0.25M | -1.45M | -2.17M |
| Selling general administrative | 0.46M | 0.29M | 0.25M | 0.93M | 1.32M |
| Selling and marketing expenses | - | - | - | - | 0.01M |
| Gross profit | 0.00M | 0.00M | 0.00M | 0.00M | -0.17M |
| Ebit | -0.50M | -0.29M | -0.25M | -0.89M | -1.52M |
| Ebitda | - | - | - | -0.93M | -1.40M |
| Depreciation and amortization | - | - | - | - | 0.12M |
| Operating income | -0.50M | -0.29M | -0.25M | -0.93M | -1.52M |
| Other operating expenses | - | - | - | 0.93M | 1.53M |
| Interest expense | 0.00M | 0.00M | 0.00M | 0.55M | 0.23M |
| Income tax expense | 0.00M | 0.00M | 0.00M | 0.00M | 0.23M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.01M |
| Total operating expenses | 0.00M | 0.00M | 0.00M | 0.93M | 1.35M |
| Cost of revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.18M |
| Total other income expense net | - | - | - | 0.03M | -0.42M |
| Net income from continuing ops | -0.55M | -0.29M | -0.25M | -1.45M | - |
| Net income applicable to common shares | -0.55M | -0.29M | -0.25M | -1.92M | - |
| Breakdown | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2013-12-31 | 2012-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2013-12-31 | 2012-12-31 |
| Total assets | 2.60M | 2.53M | 2.53M | 0.00M | 0.00M |
| Intangible assets | 2.60M | 2.53M | 2.53M | - | - |
| Other current assets | - | - | - | 0.00M | - |
| Total liab | 1.91M | 1.89M | 1.60M | 5.70M | 4.46M |
| Total stockholder equity | 0.69M | 0.64M | 0.94M | -5.70M | -4.46M |
| Other current liab | - | - | - | 2.76M | 1.22M |
| Common stock | 0.04M | 0.02M | - | 0.00M | 0.03M |
| Retained earnings | -1.09M | -0.54M | -0.25M | -51.35M | -49.43M |
| Cash | 0.00M | - | - | 0.00M | 0.00M |
| Total current liabilities | 1.91M | 1.89M | 1.60M | 4.19M | 3.43M |
| Net debt | - | - | - | 1.43M | 1.46M |
| Short term debt | 0.86M | 1.07M | 1.07M | 1.43M | 1.46M |
| Short long term debt | 0.86M | 1.07M | 1.07M | 1.78M | - |
| Short long term debt total | - | - | - | 1.43M | 1.46M |
| Other stockholder equity | 0.12M | - | - | 45.65M | 44.94M |
| Total current assets | 0.00M | - | - | 0.00M | 0.00M |
| Net tangible assets | -1.91M | -1.89M | -1.60M | -5.70M | - |
| Long term debt | - | - | - | 1.51M | - |
| Accounts payable | 1.05M | 0.82M | 0.53M | 2.42M | 0.75M |
| Non currrent assets other | - | - | - | - | 0.00M |
| Non current assets total | - | - | - | - | 0.00M |
| Breakdown | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2013-12-31 | 2012-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2013-12-31 | 2012-12-31 |
| Change to liabilities | 0.23M | 0.23M | 0.25M | 0.57M | - |
| Net borrowings | 0.21M | 0.21M | 0.21M | 0.34M | - |
| Total cash from financing activities | 0.25M | 0.25M | 0.25M | 0.37M | 0.63M |
| Change to operating activities | - | - | - | -0.00M | - |
| Net income | -0.55M | -0.29M | -0.25M | -1.45M | -2.17M |
| Change in cash | 0.00M | -0.29M | -0.29M | -0.00M | -0.00M |
| Begin period cash flow | - | - | 0.00M | 0.00M | 0.00M |
| End period cash flow | - | - | - | 0.00M | 0.00M |
| Total cash from operating activities | -0.25M | -0.29M | -0.29M | -0.37M | -0.63M |
| Depreciation | - | - | - | 0.30M | 0.12M |
| Sale purchase of stock | 0.05M | 0.05M | 0.05M | 0.02M | - |
| Other cashflows from financing activities | - | - | - | 0.37M | 0.66M |
| Change to netincome | 0.06M | 0.06M | 0.06M | 0.22M | - |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | - | - | - | 0.57M | 0.65M |
| Stock based compensation | - | - | - | - | 0.26M |
| Other non cash items | - | - | - | 0.51M | 0.52M |
| Free cash flow | - | - | - | -0.37M | -0.63M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TXTM Protext Mobility Inc |
0.00 3.85% |
0.01 | - | - | 4218.55 | - | 2997.46 | -3.17 |
| NVO Novo Nordisk A/S |
-0.68 1.64% |
40.70 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-3.02 0.55% |
547.85 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
916.06 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
ProText Mobility, Inc., a biotech company, engages in the development of pharmaceutical botanical medicines. Its medicines are formulated with highly-bioavailable plant extracts. The company is based in Boca Raton, Florida. ProText Mobility, Inc. is a subsidiary of Plandaí Biotechnology, Inc.
258 South Military Trail, Deerfield Beach, FL, United States, 33442
| Name | Title | Year Born |
|---|---|---|
| Mr. Roger Baylis-Duffield | Chairman, Pres & CEO | 1943 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.